Background. Low levels of circulating fetuin-A are associated with increased mortality in dialysis patients. This study aimed to examine a potential causative role for fetuin-A on mortality by investigating whether a functional polymorphism in the alpha2-Heremans-Schmid glyco- protein (AHSG) gene associates with mortality, and by estimating the causative effect of fetuin-A levels on mortality using a Mendelian randomization design. Methods. One thousand and forty-three incident dialysis patients were genotyped for the Thr256Ser polymorphism (rs4918) and followed up for 5 years; in 549 patients, serum fetuin-A levels were measured.
protein (AHSG) gene associates with mortality, and by estimating the causative effect of fetuin-A levels on mortality using a Mendelian randomization design. Methods. One thousand and forty-three incident dialysis patients were genotyped for the Thr256Ser polymorphism (rs4918) and followed up for 5 years; in 549 patients, serum fetuin-A levels were measured.
Results. Carriers of a serine allele displayed lower fetuin-A levels (−0.07 g/L per allele, P < 0.001). A small increased mortality risk was observed for the Thr/Ser and
Introduction
Alpha2-Heremans-Schmid glycoprotein (AHSG), colloquially known as fetuin-A, is a circulating glycoprotein synthesized in human liver tissue [1] . Fetuin-A is a potent inhibitor of calcification by inhibiting hydroxyapatite formation [2, 3] , the role of which has recently been extensively studied in patients with end-stage renal disease (ESRD). Because fetuin-A acts as a negative acute-phase protein [1] , reduced circulating levels of fetuin-A are a common feature in persistently inflamed patients, such as dialysis patients [4, 5] , patients with preeclampsia [6] and patients with rheumatoid arthritis [7] . In ESRD, studies showed that low levels of fetuin-A are associated with vascular calcification [8] [9] [10] , progression of atherosclerotic lesions [11] and increased aortic stiffness [12, 13] . Moreover, lower levels of fetuin-A have been associated with an increased risk of all-cause and cardiovascular (CV) mortality [4, 5, 10, 11] . Hermans et al. [14] showed that low levels of circulating fetuin-A are associated with increased CV and non-CV mortality, concluding that low fetuin-A concentrations may be a general predictor of mortality in dialysis patients.
In the general population, high (and not low) plasma fetuin-A levels have been found to predict increased risk of CV complications [15, 16] . As metabolic syndrome components are associated with elevated fetuin-A levels, also in the uraemic environment [17] , the association between circulating fetuin-A levels and CV outcome in ESRD may be much more complex and context sensitive than first anticipated. The cross-sectional study design of the aforementioned studies makes it impossible to answer the question whether a low circulating fetuin-A level is a risk marker or a risk factor per se. The use of a Mendelian randomization design, using a genetic variant that is associated with circulating fetuin-A levels as an instrumental variable, might provide more insight into this question [18] [19] [20] [21] . If genetic variants in the gene encoding fetuin-A are associated with mortality, this increases the likelihood that the fetuin-A protein is a causal risk factor for mortality. In a small cohort of 258 incident dialysis patients, serine allele carriers of the Thr256Ser polymorphism in the AHSG gene had lower fetuin-A levels [5] . Moreover, this study suggested higher mortality risks in these patients.
The aim of this study was to confirm or refute the hypothesis that a genetic predisposition to lower fetuin-A levels (by carriage of the serine allele) increases the risk of poor outcome in a much larger cohort of dialysis patients, and to estimate the causative effect of fetuin-A levels on mortality in a Mendelian randomization approach.
Materials and methods

Patients
The present study was performed in the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD). NECOSAD is a multi-centre cohort study, in which ESRD patients from 38 dialysis centres at the start of dialysis treatment were included between 1 January 1997 and 31 December 2006. Patients were followed up till death, kidney transplantation, refusal of further participation or till the end of the study (August 2007).
All patients gave their informed consent, and all local medical ethics committees gave their approval. Eligibility criteria were 18 years and older, and no previous renal replacement therapy. For the current analysis, we used the data of patients who were included in the study in one of the 23 centres that approved DNA analysis and had a follow-up of at least 3 months (baseline of the analysis).
Demographic and clinical data
At the start of dialysis, data were collected about age, gender, smoking, primary kidney disease, comorbidity, body mass index, systolic and diastolic blood pressure, medication use, and dialysis modality. At 3 months after the start of dialysis, blood and 24-h urine samples were obtained, and the following biochemical parameters were measured: haemoglobin, creatinine, urea, albumin, calcium, phosphorus, parathyroid hormone and high-sensitivity C-reactive protein (hsCRP). Moreover, circulating fetuin-A serum levels were measured as described elsewhere [14] . For logistical reasons, and due to limited amount of collected material, DNA and serum samples were not available in all patients in the current analysis.
Clinical definitions
Primary kidney disease and causes of death were classified and grouped according to the code of the European Renal Association-European Dialysis and Transplantation Association [22] . Patients with a history of angina pectoris, myocardial infarction or heart failure, or who had peripheral vessel damage or a cerebrovascular accident were classified as having cardiovascular disease. The comorbidity index of Khan was calculated for each patient (low, medium or high risk). Patients were classified as malnourished when having an SGA score (with a scale from 1-7) <5.
Genotyping
Patients were genotyped for the AHSG Thr256Ser (rs4918) C/G SNP using TaqMan ® SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
We verified whether the Thr256Ser genotype distribution was in HardyWeinberg equilibrium. We compared baseline characteristics between the genotype groups using the Student's t-test or Kruskal-Wallis test for continuous variables, whatever was appropriate, and a chi-square test for categorical variables. Non-normally distributed variables were logtransformed. The mean difference in fetuin-A levels per serine allele was calculated with linear regression.
The main outcome was mortality within 5 years after the start of dialysis. Kaplan-Meier analysis was performed to estimate cumulative survival curves. Hazard ratios (HRs) were calculated by Cox regression analysis. Firstly, the association between the AHSG genotype and mortality with the Thr/Thr genotype as reference genotype was calculated, and the HR for mortality per serine allele. Subsequently, the association between fetuin-A levels and mortality was analysed in order to verify the magnitude of the effect within the subgroup of NECOSAD patients with a DNA sample available. Adjustments were performed for age, sex, dialysis modality, cardiovascular disease, diabetes mellitus, body mass index, hypercholesterolaemia (cholesterol level >6.22 mmol/L) and hsCRP as potential confounding variables. In a Mendelian randomization approach, following Fisher et al. [16] , we examined the estimated causative effect of fetuin-A on mortality using the Thr256Ser polymorphism as instrumental variable [19] .
A stratified analysis was performed to search for possibly antecedents in the association of fetuin-A and outcome. We examined whether inflammation, defined as high-sensitivity CRP >10 mg/L, and diabetes are effect modifiers of the association between carriers of the serine allele and mortality. We performed similar stratified analyses for the association between fetuin-A levels and mortality.
Results
One thousand and six hundred forty-four patients were included in NECOSAD in centres that approved DNA research; 1551 of them had a follow-up of at least 3 months after the start of dialysis. DNA was available in 1043 of the 1551 patients. Of the 1043 patients, 380 died during the 5 years of follow-up, 174 due to cardiovascular causes. The 1043 patients with DNA available and the 508 patients without available DNA differed significantly in nutritional status (27% vs 37% malnourished), in the presence of cardiovascular disease (36% vs 43%), and in body mass index (BMI) (25.0 ± 4.4 vs 24.2 ± 3.9 kg/m 2 ). For 549 of the 1043 patients, circulating fetuin-A levels were measured at baseline. In these patients, the association between the AHSG genotype and circulating fetuin-A levels was determined, and the causative association between fetuin-A levels and mortality was examined using the Mendelian randomization approach. During 5 years of follow-up, 213 of the 549 patients died, 96 due to cardiovascular causes. Compared with the 494 patients who were genotyped for AHSG, but without a measurement of the fetuin-A level available, these patients differed significantly in diastolic blood pressure (82 ± 10 vs 80 ± 11 mmHg) and in phosphate levels (5.7 ± 1.8 vs 5.5 ± 1.6 mg/dL); moreover, these patients had a higher comorbidity score (medium/high according to Khan: 63% vs 54%) and were more often treated by haemodialysis (HD) (67% vs 59%).
The AHSG Thr256Ser genotype distribution was Thr/ Thr (n = 472), Thr/Ser (n = 469) and Ser/Ser (n = 102), and did not deviate significantly from Hardy-Weinberg equilibrium (P = 0.35).
Baseline characteristics of the three AHSG genotype groups are shown in Table 1 . The Ser/Ser genotype group encompassed more female patients compared with the other genotype groups. Moreover, haemoglobin levels were slightly lower in these patients, while cholesterol levels were slightly lower in patients with the Thr/Thr genotype.
AHSG genotype and fetuin-A levels
Circulating fetuin-A levels, measured in a subgroup of 549 patients, were found to be significantly different between the three genotype groups, with lower levels for serine allele carriers [Thr/Thr 0.68 ± 0.18 g/L, Thr/Ser 0.60 ± 0.14 g/L and Ser/Ser 0.54 ± 0.15 g/L, (P < 0.001)]. The mean difference in fetuin-A level per serine allele was −0.07 g/L (95% CI −0.09 to −0.05). Figure 1 shows the cumulative mortality curves for the AHSG genotypes in 1043 patients. We observed an increased risk up to 10% for the Ser/Ser genotype compared with the Thr/Thr genotype (Table 2A ). The mortality risk increased with 4% per serine allele (HR 1.04, 95% CI 0.90-1.22). Limiting the analysis to the subgroup of 549 patients with measured circulating fetuin-A levels, we observed an HR of 0.99 per serine allele (95% CI 0.81-1.21).
AHSG genotype and mortality
Fetuin-A levels and mortality
In the 549 patients with a measurement of circulating fetuin-A and all genotyped for the Thr256Ser SNP, higher fetuin-A levels were associated with a lower mortality risk: an adjusted HR of 0.89 (95% CI 0.80-1.00) was found per 0.1-g/L increase in fetuin-A levels (Table 2B) .
We used the AHSG genotype as an instrumental variable to estimate the causal effect of fetuin-A levels on mortality. Given the above-presented mean fetuin-A difference per serine allele and the HR for mortality per serine allele in the subgroup of 549 patients, the causative effect of fetuin-A on mortality was estimated, resulting in an HR of 1.01 per 0.1-g/L increase ( Figure 2 ).
Stratified analysis for inflammation and diabetes
Among the 549 patients, 163 patients were inflamed (hsCRP >10 mg/L). These patients had lower fetuin-A levels compared with non-inflamed patients (0.56 ± 0.15 vs 0.66 ± 0.17 g/L; P < 0.001). Moreover, lower fetuin-A levels were observed in inflamed patients regardless of AHSG genotype compared with non-inflamed patients, with the lowest fetuin-A levels for patients with the Ser/ Ser genotype (data not shown).
Cumulative mortality curves ( Figure 3) show increased mortality risks in inflamed patients, independent of their AHSG genotype. Carriers of a serine allele, both in inflamed and in non-inflamed patients, had no increased mortality risk compared with non-serine carriers. The protective effect of increased fetuin-A levels was more pronounced in inflamed patients than in non-inflamed patients (Table 3A) .
One hundred and twenty-four of the 549 patients were known diabetics, and 419 non-diabetics. For six patients, the diabetic status was unknown. No difference was found in fetuin-A levels for diabetics compared with non-diabetics.
A slightly increased mortality risk was found for serine allele carriers among diabetic patients. Increased fetuin-A levels were associated with a lower mortality risk in non-diabetics, but not in diabetics (Table 3B ).
Discussion
Animal studies have shown that fetuin-A-deficient mice (AHSG −/− ) have a phenotype of widespread soft-tissue and organ calcification [3] . The severity and localization of calcifications, however, depend on the genetic background of the animals [23] . Greatly enhanced vascular calcification is observed in fetuin-A/apolipoprotein E-deficient mice, especially in those exposed to a high-phosphate diet and unilateral nephrectomy [24] . These transgenic animal studies indicate a causal role of fetuin-A in inhibiting pathologic calcification. Human studies on the AHSG genotype have not, however, been able to provide confirmation in this regard. In addition, circulating fetuin-A is found as a carrier protein that stabilizes excess calcium phosphate mineral, thereby inhibiting ectopic calcification, and as such, administration of fetuin-A was suggested as a therapeutic intervention for dialysis patients [25] . Continuous variables are displayed as means (standard deviation). C-reactive protein is displayed as median and 25th-75th percentile. C-reactive protein, high-sensitive; calcium, corrected for albumin. By using a Mendelian randomization approach, we aimed to get more evidence on the potential causative role of fetuin-A on mortality. Specifically, we investigated whether the Thr256Ser polymorphism in the AHSG gene is associated with mortality in a large cohort of incident dialysis patients. We observed that individuals genetically predisposed to decreased serum fetuin-A levels had up to 10% higher mortality risk. We confirmed that serine allele carriers have lower circulating fetuin-A levels [5] and that low fetuin-A levels significantly predict mortality [4, 5, 14] . With use of the Thr256Ser polymorphism as instrumental variable, the causative effect of fetuin-A on mortality was absent.
In the general population, high fetuin-A levels have been associated with increased risk of CV complications [15, 16] . The recent study of Fisher et al., investigating 2520 subjects in a non-renal population (EPIC-Potsdam Study), showed a significant association between AHSG polymorphisms and cardiovascular disease [16] , with increased risks for the genotypes being associated with high fetuin-A levels. This study, also using a Mendelian randomization approach, successfully provided evidence that high fetuin-A has a causative role in the development of CV complications in the general population. This observation does not apply to ESRD populations.
Our findings indicate that other (non-genetic) risk factors may be influencing fetuin-A levels in ESRD patients, potentially explaining the reported association between low circulating fetuin-A levels and increased mortality [4, 5, 10, 11, 14] . Because diabetes is known to be accompanied by higher fetuin-A levels in older individuals [26] , fetuin-A levels could be a risk marker of the diabetes burden. However, in our ESRD patients, similar fetuin-A levels were observed in diabetic and non-diabetic patients, although the protective effect of high fetuin-A levels was more pronounced in non-diabetics. This latter finding is in agreement with the lack of association between fetuin-A Fig. 2 . Calculation of the estimated causative hazard ratio of fetuin-A levels on mortality, given the observed mean difference in fetuin-A levels per serine allele of the Thr256Ser polymorphism and the observed association between the Thr256Ser polymorphism and mortality in 549 patients. Fig. 3 . Cumulative mortality curves for carrying a serine allele in inflamed (hsCRP >10 mg/L) and non-inflamed patients (n = 549). levels and cardiovascular calcification observed in a cohort of 194 non-diabetic HD patients [27] . With fetuin-A being a negative acute-phase glycoprotein, it is plausible that fetuin-A links to mortality by reflecting the risk of inflammation. In our study, adjustment for hsCRP removed a very small part of the observed effect of fetuin-A on mortality. It has recently been proposed that, in addition to putative direct pro-atherogenic effects, persistent inflammation in dialysis patients may serve as a catalyst and, in the toxic uraemic milieu, modulates the effects of other concurrent risk factors, which would thereby exacerbate the vascular calcification process [28] . The stratified analysis in our patient material showed, indeed, that high fetuin-A levels were more protective in inflamed patients than in non-inflamed patients, suggesting that inflammation may be a risk modifier of the association between fetuin-A and mortality. In this direction, the association between fetuin-A and outcome has been reported to be stronger in the presence of concurrent inflammation in dialysis patients [29] . Finally, and linked to this issue, an increased mortality risk was observed by Stenvinkel et al. [5] for the subgroup of the serine allele carriers with concurrent inflammation. Our data, however, could not replicate the latter observation. In addition to the much larger size of our study (1043 vs 258 patients), differences between the Swedish cohort and the Dutch NECOSAD cohort may have contributed to the deviating findings. First, in the Swedish cohort, all individuals were Caucasians, and age above 70 years was an exclusion criterion. Nonetheless, when limiting our study to Caucasians younger than 70 years, the findings remained the same (data not shown). Second, the cohorts differ somewhat in primary kidney disease and dialysis modality, with relatively less diabetes mellitus in the NECOSAD cohort and more often HD as initial renal replacement therapy [30] .
When interpreting our results, some limitations should be taken into account. First, the number of patients included in the study, although four times higher than previous reports, was limited. The differences in observed mortality risks related to the AHSG genotype were small; more patients are needed to demonstrate these differences with higher confidence. Second, compared with the 508 NECOSAD patients from whom DNA was not available, a lower number of malnourished patients, as well as a lower number of patients with cardiovascular disease, were included in the present study, indicating that the analysis was based on a selection of slightly healthier dialysis patients. However, the observed association between fetuin-A levels and mortality was comparable with the findings of Hermans et al. [14] , which were based on the data of 987 NECOSAD patients, not limited to patients with available DNA; in that study, an HR of 0.91 (95% CI 0.84-0.99) per 0.1-g/L increase in fetuin-A levels was found. Furthermore, in addition to the assumption of the absence of other pathways between the genetic variant and the outcome, an important assumption for estimating causative relationships in a Mendelian randomization approach is that a robust association is present between the genetic variant and the exposure levels of interest [18] . In agreement with previous results [5] , the AHSG genotype was clearly associated with fetuin-A levels in our data. However, not all genetic variance in fetuin-A levels is covered by this single polymorphism, and the use of haplotypes in the AHSG gene as an instrumental variable might provide stronger evidence regarding fetuin-A as a risk marker. Finally, some residual confounding for metabolic syndrome could not be excluded in the association between fetuin-A levels and mortality, as only the data of three metabolic syndrome components were available (body mass index, diabetes and hypercholesterolaemia).
In conclusion, this Mendelian randomization study suggests that the genetic predisposition of fetuin-A, in terms of the Thr256Ser polymorphism, accounts for a minor part of the increased mortality risk of lower fetuin-A levels. We infer that the previously found associations between levels of fetuin-A and mortality must be explained at least in part by residual confounding. Other risk factors, including inflammation and diabetes, may lead to lower fetuin-A levels, and/or modify the effect of low fetuin-A on mortality in ESRD patients.
